A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight increase in new diabetic retinopathy cases but fewer severe eye complications, ...

Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg report that revealed ...

SGLT-2 inhibitor and GLP-1 receptor agonist drugs should be used in all or almost all adults with type 2 diabetes at higher ...

Current weight-loss and diabetes medications, such as GLP-1 drugs, often fail to deliver lasting results and are plagued by ...

Mounjaro prices are to double on September 1 says the pharmaceutical giant that makes the weight loss jab. The 15mg pen is expected to cost ...

The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health ...

No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) without considering cardiovascular and kidney risks, according to a BMJ ...

SGLT-2 inhibitor and GLP-1 receptor agonist drugs should be used in all or almost all adults with type 2 diabetes at higher risk of cardiovascular and ...

Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Eli Lilly for allegedly bribing and ...

Telehealth and wellness platform Hims & Hers Health ($HIMS) recently disappointed investors with its mixed second-quarter ...

Presented positive translational data from SYNGAP1-related disorders program showcasing efficacy in a humanized SYNGAP mouse model and increased protein in non-human primates at the 28th American ...

Republican leaders pushed back on the DHHS approach. They also tied the dispute to broader state budget negotiations.